The majority of patients with choroidal melanoma treated with AU-011 have maintained vision and experienced tumor control and reduced growth rate, according to interim results of a phase 1b/2 open-label clinical trial.
“Preliminary results show that AU-011 for choroidal melanoma is both safe and effective. One and two cycles of AU-011 were well tolerated. Inflammation is noted and has been manageable, and steroid therapy can be effective to control inflammation once it begins,” Prithvi Mruthyunjaya, MD, MHS, said at the virtual Association for Research in Vision and Ophthalmology
Uncategorized